Sara joined NEA's healthcare team in 2009 and focuses on investments in biopharmaceutical companies. She serves on the boards of Mersana (MRSN), Cydan, Imara, Centrexion, and Complexa, and as a board observer for Millendo. She previously served on the board of Vtesse (acquired by Sucampo) and as a board observer for Tesaro (TSRO), Ziarco (acquired by Novartis), Loxo Oncology (LOXO), Omthera (acquired by AstraZeneca), Epizyme (EPZM), Clementia (CMTA), Nightstar (NITE), and Zyngenia.  She has also been involved in NEA’s investments in Prosensa (acquired by BioMarin), Proteostasis (PTI), Arsanis (ASNS), Metacrine, 3-V Biosciences, XTuit, and Edimer. She also serves on the board of BioHealth Innovation Management. She has been selected three times as one of GrowthCap’s Top 40 Under 40 Growth Investors. Prior to joining NEA, Sara was an Associate with Merrill Lynch’s Global Healthcare Group, where she advised biotechnology, pharmaceutical and medical device companies on numerous mergers, acquisitions and financing transactions. Previously, she worked as an Investment Banking Analyst at Morgan Stanley. She has conducted basic science research in mammalian cardiac development and clinical research in age-related macular degeneration. Sara concurrently earned her MD (cum laude) and MBA from Yale University, where she was a Yale MBA Scholar. She received her AB (magna cum laude) in Biology from Harvard University.